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ABSTRACT
Objectives: This study was aimed at scientifically evaluating the in vitro antipsoriatic activity of Siddha drug Panchamuga Chendhuram (PMC) in 
human keratinocyte (HacaT) cell lines.
Methods: The Siddha drug PMC tested for antipsoriatic activity on HacaT cell lines was morphologically examined by phase contrast microscopy, and 
the cell viability was determined by 3- (4, 5 dimethyl thiazole-2 yl) -2.5-diphenyl tetrazolium bromide assay. About 100 μl of different concentrations 
(2, 6, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 μg/ml) of the test samples were prepared in the cell culture medium and incubated for 24 h and 48 h 
to determine the viable cells.
Results: The results revealed that Siddha drug PMC showed hopeful antiproliferative activity. In vitro studies showed that after 24 h and 48 h 
incubation, the inhibitory concentration 50 (IC50) values of PMC (IC50 20 μg/ml) were 72.08±27.56 μg/ml and 43.91±17.71 μg/ml, respectively, as 
compared with Asiaticoside as a positive control with an IC50 value of 20.13 μg/ml.
Conclusion: Thus, this study provides scientific evidence about the efficacy of the Siddha drug PMC against the HacaT cell lines confirming its 
traditional use in psoriasis treatment and also emphasizes the need for antipsoriatic evaluation in animal models.
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INTRODUCTION
Psoriasis is a serious global problem for many decades. Its prevalence 
rate ranges from 0.44% to 2.8% of the Indian population [1]. The 
name psoriasis was given by the Viennese dermatologist Von Hebra. 
The name is derived from the Greek word psora which means to 
itch [2]. Psoriasis is defined on a clinical basis as chronic, relapsing, 
remitting papulosquamous eruption with typical localization on the 
extensor surfaces such as elbows and knees involving scalp, genitalia 
or nails, and other sites [3]. Among the psoriasis patients, the ratio 
of male to female was 1.1:1. Among the affected patients, 12.5% 
had a family history of psoriasis [4]. Early onset disease that affects 
patients at age<40 years accounts for more than 75% of psoriasis 
cases [5].
Psoriasis is an autoimmune disorder. The immune system is not only 
the key to what causes psoriatic disease but it may also be the key 
to treating it, too. In 1979, the researchers discovered an accident 
that a drug called cyclosporine that suppresses the immune system 
also clears psoriasis. Since then, many effective treatments directed 
toward the immune system have been developed for psoriasis and 
psoriatic arthritis [6]. At present, the treatment of psoriasis composes 
of a wide range of treatment options, the prescribed synthetic drugs 
for the treatment of psoriasis are often associated with severe side 
effects; thus, researchers around the globe are searching for new, 
effective, and safer drugs from natural resources. Around 60–70% 
of the world population is using traditional medicines isolated from 
various medicinal plants. The herbal formulations are used not only 
that the herbal formulations are economical but also present lesser 
side effects when administered to control diseases and their secondary 
complications [7].
It is well known that skin diseases are cured excellently with Siddha 
medicines. There are lots of Siddha medicines indicated in Siddha 
textbooks for skin diseases. The medicines are used in two forms 
one as individual herbs and another as compound formulations. 
These are some single herbs which have potent efficacy against skin 
diseases proved by in vitro studies, Aristolochia bracteolata, Carum 
copticum, Curcuma aromatica, Indigofera aspalathoides, Nigella sativa, 
Smilax china, Wattakaka volubilis, Pongamia pinnata, Commiphora 
myrrha, Morinda tinctoria, Strychnos nux-vomica, Thespesia 
populnea, Cardiospermum halicacabum, Clerodendrum inerme, and 
Coccinia grandis. The popular Siddha compound formulations are 
parangipattai chooranam (Powder) parangi rasayanam, parangi pattai 
padhangam, kendhi mezhugu, Mahaveera Mezhugu, nandhi mezhugu, 
rasagandhi mezhugu, kandhaga parpam (Calx), muthuchippi parpam, 
sangu parpam, palagarai parpam, irunelli karpam, serangkottai nei, 
kandhaga sudar thailam, Siddhadhi ennai, and Garudan kilangu 
ennai. External oil and ointments are vetpalai thailam (oil), karappan 
thailam, arugan thailam, Punga thailam, Meganadha thailam, sirattai 
thailam, kundhriga thailam, matthan thailam, Kungiliya vennai, 
Amirtha vennai, Kizhinjal mezhugu, Vellai mezhugu, and Padai 
sangaaran [8,9]. Like single herbs the in vitro studies of compound 
Siddha formulations for skin diseases are still lacking; hence, 
the attempt is made to fill this lacuna. Panchamuga Chendhuram 
(PMC) is a Siddha Herbomineral formulation used in this study 
indicated for psoriasis in the classical Siddha textbook Pulippani 
Vaidhyam – 500 [10]. In this study, cultured cell line (spontaneously 
transformed and immortalized human keratinocyte [HacaT] cell line) 
was used which is commonly employed as an in vitro test model for the 
antiproliferative activity of new treatment due to its highly preserved 
differentiation capacity [11].
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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substance in various concentrations was added to the cells in microtiter 
plates. Test compounds were prepared in dimethyl sulfoxide (DMSO) and 
then diluted with DMEM; the final concentration of DMSO was 0.2% in the 
culture medium. Each sample concentration was tested in triplicates. The 
plates were then incubated at 370° C for 3 days in 5% CO2 atmosphere.
Antiproliferative assay
The antiproliferative activity was assessed by performing the 3- (4, 5 
dimethyl thiazole-2 yl) -2.5-diphenyl tetrazolium bromide (MTT) assay. 
The ability of the cells to survive a toxic insult has been the basis of most 
cytotoxicity assays. This assay is based on the assumption that dead 
cells or their products do not reduce tetrazolium. The assay depends 
both on the number of cells present and on the mitochondrial activity 
per cell. The cleavage of MTT to a blue formazan derivative by living 
cells is clearly a very effective of principle on which the assay is based. 
The principle involved is the cleavage of tetrazolium salt MTT into a 
blue colored product (formazan) by mitochondrial enzyme succinate 
dehydrogenase. The number of cells was found to be proportional to 
the extent of formazan production by the cells used [15].
Cells were fixed by adding 25 μl of ice-cold 50% trichloroacetic acid on 
top of the growth medium, and the plates were incubated at 40°C for 
1 h after that plates were washed to get rid of traces of medium, drug, 
and serum. MTT reagent (10 μl; 0.4% in 1% acetic acid) (Sigma) was 
added to each well and left in contact with the cells for 30 min after 
which they were washed with 1% acetic acid, rinsing 4 times until only 
dye adhering to the cells was left. The plates were then dried and 100 
μl of 10 mm Tris buffer (Sigma) added to every well to solubilize the 
dye. The plates were shaken gently for 5 min and absorbance was read 
at 550 nm using a microplate reader. The readings were taken at two 
different incubation time (24 h and 48 h). In this study, no positive 
control was used, but as the data available previously the results were 
compared to Asiaticoside. Asiaticoside is a major chemical constituent 
present in the plant Centella asiatica. The percentage inhibition was 
calculated from this data using the following formula [16]:
( )
( )
Mean OD of untreated cells 
control  –  Mean OD of treated cells
% viability 100
Mean OD of untreated cells control
= ×
Fig. 1: Panchamuga Chendhuram induced changes in morphology 
and number of human keratinocyte (HacaT) cells changes shown 
by phase contrast microscopy. As the concentration increased, 
the number of HacaT cells gradually decreased, morphological 
changes occurred
Table 2: IC50 of PMC in HacaT cell lines at 24 h and 48 h
Cell line PMC
24 h IC50 (20 µg) 48 h IC50 (60 µg)
HacaT 72.08±27.56* 43.91±17.71
Effect of PMC on HacaT at 24 h shows significant inhibitory concentration, 
IC50 (24 h) = 72.08±27.56* (p<0.05). PMC: Panchamuga Chendhuram,  
HacaT: Human Keratinocyte cell lines, IC50: Inhibitory concentration
Table 1: IC50 of PMC in HacaT cell lines at 24 h and 48 h
Concentration (μg) % of cell inhibition 
in 24 h














HacaT: Human Keratinocyte cell lines, IC50: Inhibitory concentration, 
PMC: Panchamuga Chendhuram
METHODS
Preparation of PMC [10]
Raw drugs were purchased from Raw drug shop, R. N. Rajan and co., 
Parry’s, Chennai. Authentication was made by Pharmacognosy, Siddha 
Central Research Institute, Chennai, and purification was made as per 
the Siddha classical literature [12].
Ingredients
Purified rasam (Hydragyrum), purified Gandhagam (Sulfur), purified 
Thalagam (Arsenic trisulfide), purified Lingam (Mercury II sulfide), 
purified Veeram (Mercuric chloride) each 100 g, and piper betel leaf 
juice Q.S.
Procedure
All the ingredients were ground well for 1 day and made into pellets 
(villais). The pellets were allowed to dry, and then it was ignited for 
small flame (Deepaagni) – 6 h, moderate flame (Kamalaagni) – 6 h, and 
high flame (Kaadaagni) – 9 h. After self-cooling, the product was again 
subjected to grinding for 1 day. The final product PMC was weighed and 
stored in an airtight container.
In vitro antiproliferative activity on HacaT cell lines [13,14]
Cell culture
In vitro antipsoriatic activity was carried out on HacaT cell lines. HacaT 
cell lines were obtained from NCCS, Pune, India, and the procedure was 
carried out in Tamil Nadu Veterinary and Animal Sciences University 
(TANUVAS), Chennai. The cells were seeded at a concentration of 
1.0 × 105 cells/ml in a 96 well microtiter plate and grown in Dulbecco’s 
modified eagle’s medium (DMEM, Gibco) supplemented with 10% fetal 
bovine serum (BioWest). After 24 h, the supernatant was decanted 
and therefore the monolayer was washed once. Then, 100 μl of a test 
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Fig. 2: In vitro antiproliferative activity of Panchamuga 
Chendhuram (PMC) in human keratinocyte (HacaT) cell lines. 
3- (4, 5 dimethyl thiazole-2 yl) -2.5-diphenyl tetrazolium bromide 
assay indicated that PMC inhibited the viability of HacaT cells 
in a dose-dependent manner. The drug PMC at 24 h incubation 
possess significant antiproliferative activity (inhibitory 
concentration 50 [IC50] 20 μg/ml) the mean and standard 
deviations (SD) was 72.08±27.56 μg/ml, whereas in 48 h 
incubation the activity decreases (IC50 20 μg/ml) the mean SD was 
43.91±17.71 μg/ml
Table 3: MTT assay 24 h PMC
Concentration 
(μg)
1 2 3 4 5 6 7 8 9 10 11 12
A 3.096 3.598 3.013 0.22 0.234 0.931 0.387 0.6 0.56 0.79 0.661 0.628
B 3.047 2.407 2.397 0.226 0.144 0.461 0.302 0.649 0.432 0.487 0.541 0.78
C 2.828 2.736 2.435 0.293 0.159 1.005 0.307 0.582 0.554 0.522 0.392 0.562
D
E 2.334 3.133 2.985 2.587 3.766 3.066 3.042 3.007 2.847 2.706 2.886 2.775
MTT: 3- (4, 5 dimethyl thiazole-2 yl) -2.5-diphenyl tetrazolium bromide, PMC: Panchamuga Chendhuram
Table 4: MTT assay 48 h PMC
Concentration 
(μg)
1 2 3 4 5 6 7 8 9 10 11 12
A 2.777 2.906 2.97 2.969 2.789 2.101 1.748 1.378 1.314 1.207 1.862 1.788
B 2.349 2.965 2.689 2.966 3.324 2.545 2.014 0.853 0.955 1.438 1.412 2.041
C 2.832 2.886 3.159 3.184 3.521 2.368 2.932 1.255 1.199 1.188 2.057 1.84
D
E 2.117 2.844 3.881 3.761 2.962 Overflow Overflow Overflow Overflow 3.36 2.885 2.469
A1- A12=2 μg, 6 μg, 10 μg, 20 μg, 30 μg, 40 μg, 50 μg, 60 μg, 70 μg, 80 μg, 90 μg, 100 μg, B1-B12=Duplicate, C1-C12=Triplicate, E1-E12=Cell control. MTT: 3- (4, 5 
dimethyl thiazole-2 yl) -2.5-diphenyl tetrazolium bromide, PMC: Panchamuga Chendhuram
Statistical analysis
The data were given as mean ± standard deviations (SD). The statistical 
differences were evaluated using one-way ANOVA followed by the least 
significant difference as post hoc analysis (SPSS Version 19.0; SPSS Inc., 
Chicago, IL, USA). p=0.05 was considered statistically significant.
RESULTS
The inhibitory concentration 50 (IC50) was determined as the dose 
that would be required to kill 50% of the cells with the respective 
preparation and duration. The proportion of dead cells and type of cell 
death after treatment was better illustrated from the morphological 
observations (Fig. 1). The drug PMC at 24 h incubation possess 
significant antiproliferative activity (IC50 20 μg/ml) the mean and SD 
was 72.08±27.56 μg/ml, (p<0.05) (Tables 1 and 2), whereas in 48 h 
incubation the activity decreases (IC50 20 μg/ml) the mean and SD was 
43.91±17.71 μg/ml.
DISCUSSION
Skin is the largest exposed organ of the body and is easily targeted 
for allergic and immunological reactions. Skin ailments, specifically 
dermatitis, urticaria, angioedema, psoriasis, etc., are immune-mediated 
disorders that are chronic, inflammatory, and proliferative in 
nature [17]. Psoriasis has become an important area of scientific 
study due to its severe effect on the quality of life, cost of treatment 
and toxicity, and the side effects of available medication [18,19]. 
Inhibition of hyperproliferation of epidermal keratinocytes is one of 
the key mechanisms by which most of the available antipsoriatic drugs 
act. HacaT cells are human spontaneous immortal keratinocyte cells 
and are often used as an effective model instead of primary-cultured 
keratinocytes and the data obtained from this model have shown a good 
correlation with in vivo skin irritation [11].
The drug PMC at 24 h incubation possesses significant antiproliferative 
activity, whereas in 48 h incubation the activity decreases 
(Tables 3 and 4). The effect of PMC at 48 h treatment shows only a few 
dead cells. In a study conducted by Khazaei et al., the cytotoxic activity 
of methanolic extract of bulb of Allium atroviolaceum (BAA) in MCF7, 
MDA-MB-231, HeLa and HepG2 cell lines, the results showed the BAA 
extract on MDA-MB-231 treated cells entered early apoptosis stage in 
IC25, IC50, and IC75 concentrations after 24 and 48 h. However, at 72 h, the 
proportion of early apoptotic cells decreased compared to 24 and 48 h, 
this suggested that the cell death might occur due to nutrient depletion 
in the growth media or contact inhibition [20]. In the same way, PMC 
at 24 h showed an increase in anti-proliferative activity, but after 48 h 
exposure, the activity decreases (Fig. 2) this may be due to the same 
reason dealt in the above study. This trial drug PMC was also tested 
in human breast cancer (MCF-7) cell lines in that study the IC50 values 
are constantly increasing in 24 and 48 h, this is contrary to the present 
study [21]. In the future, this study has to be carried out in animal 
models for a better understanding of the mechanism action of PMC. The 
PMC is shown IC50 20 μg/ml in 24 h with good antiproliferative activity 
when compared with Asiaticoside as a positive control with an IC50 
value of 20.13μg/ml.
A successful antipsoriatic drug that targets the epidermis is defined 
as a compound that ideally shows low toxicity and restores skin 
homeostasis by suppressing keratinocyte hyperproliferation, 
abnormal differentiation, or both [22]. The effect of PMC was observed 
in HacaT cell lines, and it is evident that the Siddha drug PMC has 
the ability to induce cell death. The probable mechanism in causing 
the cell death is by interacting with the cell membrane proteins and 
making the cell leak its cellular constituents and finally leading death, 
or maybe it is able to interact with the DNA or cell signaling pathways 
and manipulating the cellular pathways leading or triggering the cell 
death pathways [23]. To know the exact mechanism of Siddha drug 
283
Asian J Pharm Clin Res, Vol 12, Issue 6, 2019, 280-283
 Rajalakshmi et al. 
PMC, the evaluation of antiproliferative activity in an animal model 
is a must.
CONCLUSION
This study reveals the promising skin keratinocytes antiproliferative 
activity of Siddha drug PMC. Hence, the hypothesis that PMC can 
potentially be used in antipsoriatic therapy is shown. Further works on 
Siddha drug PMC need to be carried out in the treatment of psoriasis.
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